Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 5-6, 2005, Pages 376-382

  Cepek, Lukas ^a   Steinacker, Petra ^a   Mollenhauer, Brit ^a   Wiese, Birgitt ^a   Ciesielczyk, Barbara ^a   Bibl, Mirko ^a   Wiltfang, Jens ^b   Zerr, Inga ^a   Schulz Schaeffer, Walter ^a   Kretzschmar, Hans A ^c   Poser, Sigrid ^a   Otto, Markus ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Creutzfeldt Jakob disease; S 100B; Tau protein

Indexed keywords

PROTEIN S100B; TAU PROTEIN;

ADULT; AGED; ARTICLE; CALCULATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MALE; NEUROLOGIC DISEASE; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CREUTZFELDT-JAKOB SYNDROME; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; ENCEPHALITIS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; S100 PROTEINS; TAU PROTEINS; UREMIA;

EID: 20844454083     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084708     Document Type: Article

References (29)

1. Steinhoff BJ, Racker S, Herrendorf G, et al: Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996;53:162-166.
2. Otto M, Wiltfang J, Cepek L, et al: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-197.
3. Otto M, Wiltfang J, Tumani H, et al: Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-212.
4. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E: Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2001;71:401-403.
5. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P: A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210-1214.
6. Beaudry P, Cohen P, Brandel JP, et al: 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999;10:40-46.
7. Otto M, Stein H, Szudra A, et al: S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566-570.
8. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
9. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ, Jr: An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000;48:395-398.
10. Zerr I, Bodemer M, Gefeller O, et al: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-40.
11. WHO: Consensus on criteria for sporadic CJD. Geneva, WHO, 1998. http://www.who.int/emc-documents/tse/docs/whoemczdi989.pdf.
12. Green AJ, Knight RS, Macleod MA, Lowman A, Will RG: Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2001;56:986-987.
13. Green AJ, Thompson EJ, Stewart GE, et al: Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001;70:744-748.
14. Aksamit AJ: Cerebrospinal fluid 14-3-3 protein: Variability of sporadic Creutzfeldt-Jakob disease, laboratory standards, and quantitation. Arch Neurol 2003;60:803-804.
15. Geschwind MD, Martindale J, Miller D, et al: Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60:813-816.
16. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J: Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996;53:913-920.
17. Bieschke J, Giese A, Schulz-Schaeffer W, et al: Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 2000;97:5468-5473.
18. Hill AF, Butterworth RJ, Joiner S, et al: Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-189.
19. Galasko D, Chang L, Motter R, et al: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
20. Hulstaert F, Blennow K, Ivanoiu A, et al: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
21. Frank RA, Galasko D, Hampel H, et al: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521-536.
22. Verbeek MM, De Jong D, Kremer HP: Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003;40:25-40.
23. Masters CL, Harris JO, Gajdusek DC, Gibbs CJJ, Bernoulli C, Asher DM: Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188.
24. Will RG: Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993;49:960-970.
25. Parchi P, Castellani R, Capellari S, et al: Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996;39:767-778.
26. Otto M, Wiltfang J, Schütz E, et al: Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case-control study. BMJ 1998;316:577-582.
27. Jimi T, Wakayama Y, Shibuya S, et al: High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992;211:37-46.
28. Van Everbroeck B, Green A, Vanmechelen E, et al: Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002;73:79-81.
29. Wiltfang J, Esselmann H, Smirnov A, et al: Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003;54:263-267.